LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

S&P 500® EPS growth expected to come in at 13.2%, the highest growth rate in three years Large cap outlier earnings dates ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

Barclays analyst Luke Sergott maintained a Buy rating on IQVIA Holdings (IQV – Research Report) today and set a price target of $235.00. The ...